Tynterova A M, Barantsevich E R
Imannuel Kant Baltic Federal University, Kaliningrad, Russia.
Pavlov Federal Saint Petersburg State Medical University, St Petersburg, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2024;124(8. Vyp. 2):14-20. doi: 10.17116/jnevro202412408214.
To assess phenotype and identify biomarkers of cognitive impairment (CI) of varying severity in patients in the acute period of ischemic stroke (IS) based on the analysis of clinical and paraclinical indicators.
Two hundred and forty patients with diagnosed IS and presence of CI were examined. Depending on the scores on the Montreal Cognitive Assessment Scale, patients were divided into two groups: group 1 (=182) with mild CI, group 2 (=58) with dementia. On admission, stroke severity according to the National Institutes of Health Stroke Scale (NIHSS), activities of daily living assessed by the Barthel Scale and patient independence assessed by the modified Rankin Scale (mRS) were determined. Neuropsychological examination was performed on day 14 and included investigation of episodic memory, executive functions, speech, gnosis, praxis, and the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) parameters. Immunological diagnostics included a study of the concentration of cytokines of various groups (interleukin (IL)-1b, IL-6, IL-16, granulocyte-macrophage colony-stimulating factor (GM-CSF), chemokines CXCL10, CXCL11, CXCL9, tumor necrosis factor α (TNFα)). Neuroimaging parameters were assessed using brain MRI data with verification of the STRIVE criteria and the medial temporal lobe atrophy scale (MTA). The standard application software package SPSS Statistics, Pandas and SciPy libraries were used for statistical analysis.
Patients of group 2 had lower scores in all cognitive domains with the greatest reduction in perception, constructive praxis, semantic information processing and mnestic function. These analyses revealed a higher degree of IQCODE, prevalence of features corresponding to STRIVE/MTA criteria in patients of group 2, while patients of group 1 had higher NIHSS and mRS scores. When serum concentrations of cytokines were assessed, patients of group 1 showed higher concentrations of IL-1b, IL-6, GM-CSF and TNFα, while group 2 patients had higher concentrations of cytokine CXCL10.
The presence of pre-stroke CI, baseline indicators of the patient's functional status, neuroimaging parameters of MTA/STRIVE and age are reflected in the structure and severity of cognitive deficit in the acute period of IS. Investigation of the role of interleukins, GM-CSF, TNFα and CXCL10 in the pathogenesis of IS and their association with the progression of post-stroke CI requires further studies with a larger sample size and longer follow-up period.
基于临床和辅助临床指标分析,评估缺血性卒中(IS)急性期患者不同严重程度认知障碍(CI)的表型并识别其生物标志物。
对240例确诊为IS且存在CI的患者进行检查。根据蒙特利尔认知评估量表得分,将患者分为两组:轻度CI组(n = 182),痴呆组(n = 58)。入院时,根据美国国立卫生研究院卒中量表(NIHSS)确定卒中严重程度,采用巴氏量表评估日常生活活动能力,采用改良Rankin量表(mRS)评估患者独立性。在第14天进行神经心理学检查,包括情景记忆、执行功能、言语、认知、实践能力以及老年人认知功能减退 informant 问卷(IQCODE)参数的调查。免疫诊断包括研究各类细胞因子(白细胞介素(IL)-1β、IL-6、IL-16、粒细胞巨噬细胞集落刺激因子(GM-CSF)、趋化因子CXCL10、CXCL11、CXCL9、肿瘤坏死因子α(TNFα))的浓度。使用符合 STRIVE 标准和内侧颞叶萎缩量表(MTA)的脑 MRI 数据评估神经影像学参数。使用标准应用软件包SPSS Statistics、Pandas和SciPy库进行统计分析。
第2组患者在所有认知领域的得分均较低,其中感知、建设性实践、语义信息处理和记忆功能下降最为明显。这些分析显示,第2组患者的IQCODE程度更高,符合STRIVE/MTA标准的特征患病率更高,而第1组患者的NIHSS和mRS得分更高。评估血清细胞因子浓度时,第1组患者的IL-1β、IL-6、GM-CSF和TNFα浓度较高,而第2组患者的细胞因子CXCL10浓度较高。
卒中前CI的存在、患者功能状态的基线指标、MTA/STRIVE的神经影像学参数和年龄反映在IS急性期认知缺陷的结构和严重程度中。对白介素、GM-CSF、TNFα和CXCL10在IS发病机制中的作用及其与卒中后CI进展的关联进行研究,需要进一步开展样本量更大、随访期更长的研究。